Development
Cullinan Therapeutics, Inc.
CGEM
$7.85
-$0.235-2.91%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 11.12% | -57.97% | -118.42% | -379.10% | 17.63% |
| Total Depreciation and Amortization | 30.51% | 788.89% | 575.00% | 453.85% | 391.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -66.15% | -3.98% | 102.32% | 144.46% | -41.69% |
| Change in Net Operating Assets | 166.05% | 99.48% | -109.67% | -61.03% | -187.10% |
| Cash from Operations | 27.43% | 37.19% | -21.97% | -132.78% | -64.68% |
| Capital Expenditure | 100.00% | 100.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 285.02% | 31.52% | -60.59% | -55.80% | -75.38% |
| Cash from Investing | 279.90% | 25.91% | -95.97% | -56.26% | -80.37% |
| Total Debt Issued | -100.00% | -- | -100.00% | 128.13% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 27.84% | -92.14% | 1,270.99% | -- | -92.82% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -103.12% | -- |
| Cash from Financing | 100.75% | -92.14% | 1,817.64% | -49.48% | -1,318.06% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 138.83% | 30.58% | -92.90% | -308.17% | -205.34% |